Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an announcement.
Argenica Therapeutics has announced positive outcomes from the Data Safety Monitoring Board (DSMB) review of its Phase 2 clinical trial for ARG-007 in acute ischaemic stroke (AIS) patients. The DSMB recommended the trial continue without modifications, affirming its safety and protocol integrity. With 86% of patient dosing complete and recruitment progressing well, Argenica expects to finish dosing by early Q2 2025, which positions the company favorably in the neurological therapeutic market.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other neurological conditions.
YTD Price Performance: 2.38%
Average Trading Volume: 121,798
Technical Sentiment Consensus Rating: Hold
See more insights into AGN stock on TipRanks’ Stock Analysis page.
